3 results
Approved WMOCompleted
In this study, the main clinical hypothesis is that the TIMI clinically significant bleeding rates will not be different between the rivaroxaban and VKA treatment strategy groups at Month 12.
Approved WMOCompleted
To evaluate the safety and efficacy of PRX-102 compared to agalsidase beta in Fabry disease patients with impaired renal function.
Approved WMOCompleted
To evaluate the safety and efficacy of PRX-102 in patients with Fabry disease currently treated with agalsidase alfa